PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES

• P. Knoebl,
• H. de Haard,
• W. Parys,
• P. Ulrichts,
• F. Rocca,
• A. Guglietta,
• J. Ayguasanosa

Affiliations

P. Knoebl

1 Medical University of Vienna, Vienna, Austria

H. de Haard

2 argenx, Ghent, Belgium

W. Parys

2 argenx, Ghent, Belgium

P. Ulrichts

2 argenx, Ghent, Belgium

F. Rocca

2 argenx, Ghent, Belgium

A. Guglietta

2 argenx, Ghent, Belgium

J. Ayguasanosa

2 argenx, Ghent, Belgium